Related Experiment Video
Updated: May 6, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target
Renxuan Lin1, Hiocheng Un1, Youmei Kang2
1Department of Urology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background:
Senescence plays a critical role in prostate cancer, influencing disease onset and progression. However, the alterations of senescence-associated genes during prostate cancer progression and their potential value in predicting disease advancement remain to be further elucidated.
Methods:
117 machine learning methods were applied to construct the senescence-related gene signature (SRGS). Temporal trajectory analysis based on bulk and single-cell transcriptomic datasets was performed to link SRGS with prostate cancer progression. Functional validations of PCNA were conducted both in vitro and in vivo to support our analytical findings.
Results:
Using 117 machine learning methods, we developed the SRGS, which demonstrated robust predictive capability across multiple cohorts, including our own cohort of 90 patients. The SRGS also showed strong potential in predicting overall survival in patients treated with second-generation AR inhibitors. Temporal trajectory analysis of bulk RNA-seq and single-cell data revealed the biological significance of SRGS and identified Proliferating Cell Nuclear Antigen (PCNA) as a potential driver of PCa progression. Pharmacological inhibition of PCNA with AOH1996 significantly suppressed tumor growth and enhanced the efficacy of androgen deprivation therapy.
Conclusion:
We developed the SRGS that effectively predicts prostate cancer prognosis and progression. Moreover, our findings highlight PCNA as a promising therapeutic target in PCa. Integrated analysis of multi-cohort transcriptomic data developed an SRGS enabling accurate prognostication and identification of high-risk patients. Results highlight SRGS's clinical utility and nominate PCNA as a promising therapeutic target in high-risk and castration-resistant prostate cancer (CRPC).
